1. Misleading localization by 18F-fluorocholine PET/CT in familial hypocalciuric hypercalcemia type-3: a case report
- Author
-
Mohammed H Al-Qahtani, Mohei El-Din M. Abouzied, Muhammad M. Hammami, and Noha N Mukhtar
- Subjects
Adult ,Parathyroidectomy ,medicine.medical_specialty ,Adaptor Protein Complex sigma Subunits ,Primary hyperparathyroidism ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,18F-fluorocholine positron emission tomography/ computed tomography ,Adaptor Protein Complex 2 ,Urology ,Parathyroid hormone ,Case Report ,Kidney ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Choline ,030218 nuclear medicine & medical imaging ,Parathyroid Glands ,03 medical and health sciences ,0302 clinical medicine ,Bone Density ,Positron Emission Tomography Computed Tomography ,medicine ,Humans ,PET-CT ,lcsh:RC648-665 ,Familial hypocalciuric hypercalcemia ,business.industry ,Thyroid ,General Medicine ,Hyperparathyroidism, Primary ,medicine.disease ,Urinary calcium ,Treatment Outcome ,medicine.anatomical_structure ,Parathyroid Hormone ,030220 oncology & carcinogenesis ,Hypercalcemia ,Calcium ,Female ,Kidney stones ,False positive localization ,Radiopharmaceuticals ,business ,Familial hypocalciuric hypercalcemia type-3 - Abstract
Background Familial hypocalciuric hypercalcemia (FHH) is a heterogeneous autosomal-dominant disorder of calcium hemostasis that may be difficult to distinguish clinically from mild primary hyperparathyroidism. Loss-of-function mutations mainly involving Arg15 residue of the adaptor-related protein complex 2, sigma subunit 1 (AP2S1) cause a rarer, more recently recognized form of FHH, FFH type-3. Recently, 18F-fluorocholine positron emission tomography/computed tomography (FCH-PET/CT) showed superior sensitivity to conventional imaging in localizing parathyroid adenomas. We report a new FFH type-3 patient who underwent unnecessary parathyroidectomy in association with misleading FCH-PET/CT imaging. Case presentation A 29-year old woman was initially evaluated for parathyroid hormone (PTH)-dependent hypercalcemia in 2013. Medical history was positive only for chronic constipation and malaise with no personal or family history of hypercalcemia, kidney stones, or neck surgery. Over seven years, serum calcium level was 2.51–2.89 mmol/L with concomitant PTH level of 58.7–94.8 mmol/L. Serum phosphate levels were in the low/low normal range. Serum creatinine and magnesium levels were normal. 25-hydroxy vitamin D level was 13 nmol/L. 24-hour urine calcium level was 1.92 mmol/day but increased to 6.99 mmol/day after treatment with cholecalciferol 1000 IU daily. Bone mineral density and renal ultrasound were normal. Parathyroid ultrasound showed two hypoechoic nodules inferior to the left and right thyroid lobes; however, 99mtechnitium-sestamibi scans (2013, 2016, 2018) were negative. FCH-PET/CT (2019) showed focal uptake co-localizing with the nodule inferior to the left thyroid lobe. The patient underwent left inferior parathyroidectomy and pathology was consistent with parathyroid hyperplasia. However, postoperatively, serum calcium and PTH levels remained elevated and FCH-PET/CT and ultrasound showed persistence of the uptake/nodule. Whole exome sequencing showed Arg15Cys mutation in the AP2S1 gene characteristic of FHH type-3. Conclusions In this new case of FHH type-3, FCH-PET/CT failed to localize to the hyperplastic parathyroid glands and localized instead to apparently a lymph node. This, together with increased urinary calcium after vitamin D supplementation, led to unnecessary parathyroidectomy. Given the increasingly lower cost of genetic testing and the cost of follow up and unnecessary surgery, it may prudent to include genetic testing for FHH early on in patients with mild PTH-dependent hypercalcemia.
- Published
- 2021